Paclitaxel repackaged in an albumin-stabilized nanoparticle: Handy or just a dandy?

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 7765-7767

  Sparreboom, Alex ^a   Baker, Sharyn D ^a   Verweij, Jaap ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; CREMOPHOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EXCIPIENT; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT; NANOPARTICLE; PACLITAXEL; PHOTOSENSITIZING AGENT; SEDATIVE AGENT; STEROID; TAXANE DERIVATIVE; TENIPOSIDE; ALBUMINOID; ANTINEOPLASTIC AGENT; NANOMATERIAL;

BLOOD TOXICITY; BREAST CANCER; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DYSPNEA; EDITORIAL; ENZYME POLYMORPHISM; FATIGUE; FLUSHING; HUMAN; HYPERSENSITIVITY REACTION; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; SOLUBILIZATION; URTICARIA; CHEMISTRY; DRUG PACKAGING; DRUG STABILITY; METABOLISM; NEOPLASM; NOTE;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG PACKAGING; DRUG STABILITY; HUMANS; NANOSTRUCTURES; NEOPLASMS; PACLITAXEL;

EID: 32944455135     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.7135     Document Type: Editorial

References (25)

1. Baldrick P: Pharmaceutical excipient development: the need for preclinical guidance. Regul Toxicol Pharmacol 32:210-218, 2000
2. Ten Tije AJ, Verweij J, Loos WJ, et al: Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 42:665-685, 2003
3. Szebeni J: Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit Rev Ther Drug Carrier Syst 18:567-606, 2001
4. Website: http://www.taxol.com, last accessed: August 24, 2005
5. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
6. Henningsson A, Karlsson MO, Vigano L, et al: Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19:4065-4073, 2001
7. Nyman DW, Campbell KJ, Hersh E, et al: A phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel stabilized with human serum albumin, administered weekly for 3 doses every 4 weeks in patients with advanced non-hematologic malignancies. J Clin Oncol 23:7785-7793, 2005
8. Mielke S, Sparreboom A, Mross K: Peripheral neuropathy: A persisting challenge in paclitaxel-based regimens. Eur J Cancer 2005 (in press)
9. Ibrahim NK, Desai N, Legha S, et al: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044, 2002
10. Ibrahim NK, Samuels B, Page R, et al: Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23:6019-6026, 2005
11. Gradishar WJ, Tjulandin S, Davidson N, et al: Superior efficacy of nanoparticle albumin-bound paclitaxel (Abraxane, ABI-007) compared with Polyethylated Castor Oil-based paclitaxel (Taxol) in women with metastatic breast cancer: Results of a phase III trial. J Clin Oncol 23:7794-7803, 2005
12. Engels FK, Sparreboom A, Mathot RA, et al: Potential for improvement of docetaxel-based chemotherapy: A pharmacological review. Br J Cancer 93:173-177, 2005
13. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992, 2005
14. Engels FK, Verweij J: Docetaxel administration schedule: From fever to tears? A review of randomised studies. Eur J Cancer 41:1117-1126, 2005
15. Sparreboom A, Scripture CD, Trieu V, et al: Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11:4136-4143, 2005
16. Mielke S, Sparreboom A, Steinberg SM, et al: Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11:4843-4850, 2005
17. Yeh TK, Lu Z, Wientjes MG, et al: Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 22:867-874, 2005
18. Harris JW, Rahman A, Kim BR, et al: Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035, 1994
19. Rahman A, Korzekwa KR, Grogan J, et al: Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546, 1994
20. Sparreboom A, van Asperen J, Mayer U, et al: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94:2031-2035, 1997
21. Smith NF, Acharya MR, Desai N, et al: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4:815-818, 2005
22. Huisman M, Chhatta AA, Van Tellingen O, et al: MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116:824-829, 2005
23. Hopper-Borge E, Chen ZS, Shchaveleva I, et al: Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): Resistance to docetaxel. Cancer Res 64:4927-4930, 2004
24. Ng SS, Figg WD, Sparreboom A: Taxane-mediated antiangiogenesis in vitro: Influence of formulation vehicles and binding proteins. Cancer Res 64:821-824, 2004
25. Ng SS, Sparreboom A, Shaked Y, et al: Metronomic ABI-007 therapy: Antiangiogenic and antitumor activity of a nanoparticle albumin-bound paclitaxel. Proc Am Assoc Cancer Res 46:702, 2005 (abstr 2988)